Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis.

Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M, Forte D, Luatti S, Cavo M, Vianelli N, Jandus C, Palandri F, Catani L.

Oncoimmunology. 2017 Jul 5;6(10):e1345402. doi: 10.1080/2162402X.2017.1345402. eCollection 2017.

2.

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.

Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, Castagnetti F, Tiribelli M, Gugliotta G, Martinelli G, Baccarani M, Cavo M, Rosti G, Testoni N.

Oncotarget. 2017 May 2;8(18):29906-29913. doi: 10.18632/oncotarget.15369.

3.

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.

Sollazzo D, Forte D, Polverelli N, Perricone M, Romano M, Luatti S, Vianelli N, Cavo M, Palandri F, Catani L.

Mediators Inflamm. 2016;2016:5860657. Epub 2016 Sep 8.

4.

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.

Sollazzo D, Forte D, Polverelli N, Romano M, Perricone M, Rossi L, Ottaviani E, Luatti S, Martinelli G, Vianelli N, Cavo M, Palandri F, Catani L.

Oncotarget. 2016 Jul 12;7(28):43974-43988. doi: 10.18632/oncotarget.9949.

5.

Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.

Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, Ameli G, Bardi MA, Bonaldi L, Paolini R, Gurrieri C, Rigolin GM, Cuneo A, Martinelli G, Cavo M, Testoni N.

Genes Chromosomes Cancer. 2016 Apr;55(4):375-88. doi: 10.1002/gcc.22341. Epub 2016 Jan 27.

PMID:
26815134
6.

FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features.

Baldazzi C, Luatti S, Paolini S, Papayannidis C, Marzocchi G, Ameli G, Martinelli G, Cavo M, Testoni N.

Am J Hematol. 2016 Mar;91(3):E14-6. doi: 10.1002/ajh.24276. No abstract available.

7.

BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia.

Leo E, Mancini M, Aluigi M, Luatti S, Castagnetti F, Testoni N, Soverini S, Santucci MA, Martinelli G.

PLoS One. 2013 Dec 10;8(12):e81425. doi: 10.1371/journal.pone.0081425. eCollection 2013.

8.

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML.

Blood. 2012 Jul 26;120(4):761-7. Epub 2012 Jun 12. Erratum in: Blood. 2013 Jun 27;121(26):5259. Cambrin, Rege [corrected to Rege-Cambrin, Giovanna].

9.

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

Soverini S, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccarani M, Martinelli G.

Leuk Res. 2011 Nov;35(11):1527-9. doi: 10.1016/j.leukres.2011.05.029. Epub 2011 Jul 16.

PMID:
21762985
10.

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G, Testoni N; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia.

Blood. 2011 Jun 23;117(25):6793-800. doi: 10.1182/blood-2011-01-328294. Epub 2011 Mar 29.

11.

B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.

Baldazzi C, Iacobucci I, Luatti S, Ottaviani E, Marzocchi G, Paolini S, Stacchini M, Papayannidis C, Gamberini C, Martinelli G, Baccarani M, Testoni N.

Leuk Res. 2010 Oct;34(10):e282-5. doi: 10.1016/j.leukres.2010.05.009. Epub 2010 Jun 9. No abstract available.

PMID:
20594995
12.

Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.

Zaccaria A, Testoni N, Valenti AM, Luatti S, Tonelli M, Marzocchi G, Cipriani R, Baldazzi C, Giannini B, Stacchini M, Gamberini C, Castagnetti F, Rosti G, Azzena A, Cavazzini F, Cianciulli AM, Dalsass A, Donti E, Giugliano E, Gozzetti A, Grimoldi MG, Ronconi S, Santoro A, Spedicato F, Zanatta L, Baccarani M; GIMEMA Working Party on CML.

Cancer Genet Cytogenet. 2010 Jun;199(2):76-80. doi: 10.1016/j.cancergencyto.2010.02.003.

PMID:
20471509
13.

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.

Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I, Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G.

J Clin Oncol. 2010 Jun 1;28(16):2748-54. doi: 10.1200/JCO.2009.26.7963. Epub 2010 May 3.

PMID:
20439635
14.

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party.

Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12.

15.

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.

Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, Abruzzese E, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P, Cuneo A, Albano F, Fugazza G, Zaccaria A, Martinelli G, Pane F, Rosti G, Baccarani M.

Blood. 2009 Dec 3;114(24):4939-43. doi: 10.1182/blood-2009-07-229864. Epub 2009 Oct 1.

16.

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.

Palandri F, Castagnetti F, Soverini S, Poerio A, Gugliotta G, Luatti S, Amabile M, Martinelli G, Rosti G, Baccarani M.

Haematologica. 2009 Dec;94(12):1758-61. doi: 10.3324/haematol.2009.010496. Epub 2009 Jul 16.

17.

Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.

Baldazzi C, Luatti S, Marzocchi G, Stacchini M, Gamberini C, Castagnetti F, Palandri F, Rosti G, Baccarani M, Testoni N.

Leuk Res. 2009 Dec;33(12):e218-20. doi: 10.1016/j.leukres.2009.05.010. Epub 2009 Jun 13. No abstract available.

PMID:
19525008
18.

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11.

19.

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.

Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G.

Haematologica. 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14.

20.

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.

Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, Castagnetti F, Breccia M, Specchia G, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G.

Leuk Lymphoma. 2009 Jan;50(1):114-8. doi: 10.1080/10428190802492415. No abstract available.

PMID:
19125382
21.

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6.

22.

Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement: clinical implications.

Luatti S, Marzocchi G, Ottaviani E, Baldazzi C, Stacchini M, Gamberini C, Salmi F, Martinelli G, Baccarani M, Testoni N.

Leuk Res. 2008 Dec;32(12):1941-3. doi: 10.1016/j.leukres.2008.03.026. Epub 2008 May 12. No abstract available.

PMID:
18468683
23.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Mar;92(3):401-4.

24.

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M.

J Clin Oncol. 2006 Nov 20;24(33):e51-2. No abstract available.

PMID:
17114651
25.

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M.

J Clin Oncol. 2005 Jun 20;23(18):4100-9. Epub 2005 May 2.

PMID:
15867198
26.

Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia.

Nicci C, Ottaviani E, Luatti S, Grafone T, Tonelli M, Motta MR, Malagola M, Marzocchi G, Martinelli G, Baccarani M, Testoni N.

Leukemia. 2005 Mar;19(3):470-2. No abstract available.

PMID:
15674421
27.

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.

Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Blood. 2004 Dec 15;104(13):4245-51. Epub 2004 Aug 19.

28.

Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia.

Piccaluga PP, Luatti S, Ascani S, Bianchini M, Malagola M, Rondoni M, Gaitani S, Testoni N, Pileri SA, Baccarani M, Martinelli G, Visani G.

Cancer Genet Cytogenet. 2004 May;151(1):85-6. No abstract available.

PMID:
15120916
29.

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.

Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, Soverini S, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M; Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia.

Blood. 2004 Mar 15;103(6):2284-90. Epub 2003 Nov 26.

30.

Interleukin-4 downregulates nuclear factor-erythroid 2 (NF-E2) expression in primary megakaryocytes and in megakaryoblastic cell lines.

Catani L, Amabile M, Luatti S, Valdrè L, Vianelli N, Martinelli G, Tura S.

Stem Cells. 2001;19(4):339-47.

31.

Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets.

Catani L, Vianelli N, Luatti S, Rizzi S, Castellani S, Valdrè L, Lemoli RM, Tura S.

Bone Marrow Transplant. 1999 Dec;24(11):1191-4.

Supplemental Content

Loading ...
Support Center